This reference uses the specific documents linked in the article and listed below. Check their scope, publication dates and the statements they support.
Exposure is commoner than clinical nervous-system disease
Sarcocystis neurona has a life cycle involving opossums as definitive hosts and other animals as intermediate hosts. Horses can ingest infectious stages in contaminated feed or water and are considered aberrant, usually dead-end hosts. Only a proportion of exposed horses develop clinical EPM. Ordinary contact with a neurologically affected horse is not the usual transmission pathway for S. neurona.
Neospora hughesi is a separate protozoal cause with less completely understood natural hosts and transmission. Its biology should not be filled in by copying the opossum cycle. This distinction matters when interpreting tests and prevention advice: a broad claim about all EPM being caused by direct contact with opossums or spread between stablemates would be misleading.
Source: Equine protozoal myeloencephalitis: an updated consensus statement; Infectious disease guidelines: equine protozoal myeloencephalitis; Equine protozoal myeloencephalitis.
The location of nervous-system damage determines the signs
EPM can involve the spinal cord, brainstem or other brain regions. Asymmetric weakness or incoordination and localized neurogenic muscle wasting are useful clues, but symmetric signs can also occur. A horse may show unusual limb placement, an apparent lameness that does not localize normally, facial weakness, difficulty swallowing or vestibular signs.
The range is broad because the organisms do not affect one fixed anatomical location in every case. Lack of fever does not exclude EPM, and a mild initial deficit can progress. Stop ridden work and seek prompt veterinary assessment for unexplained neurologic signs. Recumbency, severe incoordination, seizures, altered awareness or swallowing difficulty increases urgency and requires attention to immediate safety and nursing.
Source: Equine protozoal myeloencephalitis; Infectious disease guidelines: equine protozoal myeloencephalitis; Equine protozoal myeloencephalitis: an updated consensus statement.
A blood antibody test is not a stand-alone diagnosis
A positive serum antibody result indicates current or previous exposure. In regions where exposure is frequent, many neurologically normal horses are positive. Treating every positive result as clinical disease risks overlooking cervical compression, EDM, injury or another infection.
Paired blood and cerebrospinal-fluid testing can help assess whether antibody production is occurring within the nervous system. The veterinarian selects and interprets the assay in relation to the neurologic findings, test characteristics, sample quality and other explanations. An early infection can complicate negative-result interpretation. Neither a high blood titer nor an isolated panel result replaces clinical localization and differential diagnosis.
Source: Equine protozoal myeloencephalitis testing; Equine protozoal myeloencephalitis: an updated consensus statement; Equine protozoal myeloencephalitis.
Other causes of ataxia must be investigated seriously
Cervical spinal-cord compression can resemble EPM, as can EDM and several infectious or inflammatory neurologic disorders. The veterinarian uses age, progression, examination and local disease context to prioritize imaging and laboratory tests. A structural lesion that convincingly explains the signs should not be ignored simply because serum antibody is positive.
EPM is generally a presumptive diagnosis during life rather than a simple yes-or-no screening result. Response to treatment can support a clinical assessment but is not uniquely diagnostic: signs fluctuate and supportive care can affect function. If a horse fails to improve, repeatedly purchasing another antiprotozoal course without reconsidering the diagnosis may delay more useful investigation.
Source: Equine protozoal myeloencephalitis: an updated consensus statement; Neurologic conditions in the sport horse; Equine protozoal myeloencephalitis testing.
Treatment targets the parasite and the consequences of injury
Veterinary care uses an appropriate antiprotozoal treatment, with supportive or anti-inflammatory care selected for the patient. Drug choice and duration depend on the diagnosis, response, adverse effects and product availability in the relevant jurisdiction. Some proposed adjuncts have limited evidence and should not be presented as guaranteed accelerators of nerve repair.
Nutrition, safe access to feed and water, eye protection or swallowing support may be needed according to the deficits. Eliminating susceptible organisms does not instantly repair damaged nervous tissue. Treatment decisions are therefore guided by repeated clinical assessment rather than by demanding that an antibody result become negative. Persistent antibodies alone do not establish active treatment failure.
Source: Equine protozoal myeloencephalitis; Equine protozoal myeloencephalitis: an updated consensus statement; Infectious disease guidelines: equine protozoal myeloencephalitis.
Recovery, relapse and return to use are separate questions
Many treated horses improve, but complete recovery is less common and relapse can occur. Improvement by a neurologic grade is meaningful without necessarily restoring safe athletic performance. The horse’s actual balance, strength, cranial-nerve function and ability to negotiate ordinary surroundings must inform any return-to-work decision.
A renewed deficit should prompt reassessment for relapse and for another cause, especially if the pattern differs from the original episode. It should not automatically trigger indefinite treatment based solely on an old positive blood test. Prognosis is more useful when described in terms of the individual horse’s residual function and welfare than as a promise based on a population response percentage.
Source: Equine protozoal myeloencephalitis; Equine protozoal myeloencephalitis: an updated consensus statement.
Reduce contamination opportunities without promising complete prevention
Protect feed stores and feeding areas from wildlife access, secure containers and avoid leaving feed or attractive waste exposed. Water and feed hygiene should focus on reducing fecal contamination. Manage wildlife through lawful, appropriate local methods rather than assuming that removal of every possible intermediate host will prevent disease.
These precautions reduce plausible exposure opportunities but cannot guarantee prevention. The available veterinary guidance does not support a routine preventive antiprotozoal protocol for every horse. Any proposed preventive medication should be discussed in relation to actual evidence and risk, while maintaining the basic distinction between environmental exposure and the uncommon event of clinical nervous-system disease.
Source: Equine protozoal myeloencephalitis; Infectious disease guidelines: equine protozoal myeloencephalitis; Equine protozoal myeloencephalitis: an updated consensus statement.
Practical questions
Does a positive EPM blood test mean my horse needs treatment?
Not by itself. It demonstrates exposure. Treatment decisions require a compatible neurologic examination and appropriately interpreted additional evidence.
Can the other horses catch EPM directly from this horse?
Direct spread from a horse is not the usual S. neurona pathway. Environmental contamination of feed or water is the principal concern; the veterinarian can assess the specific setting.
Can a treated horse remain uncoordinated?
Yes. Existing nervous-system damage can persist after treatment. Function and welfare should be reassessed before any return to ridden work.
Related animal-health reading
Cite this reference
LivestockDefense. “Equine protozoal myeloencephalitis: neurologic signs, testing and treatment.” Updated 2026-11-02. https://livestockdefense.com/threats/equine-protozoal-myeloencephalitis/
Add the date you accessed the page. This identifies the current reference; keep a permitted saved copy if your work depends on its exact wording. A citation alone does not establish support for a claim.
How to cite a page and its revision ↗Sources & boundaries
Read the evidence in context.
These documents support the statements identified in this reference. Check their scope and dates when deciding whether they answer your question.
- Frontiers in Veterinary Science / veterinary clinical review: Neurologic conditions in the sport horse
Source update: 2022. Most recent check: 2026-11-02.
Condition-specific comparison of CVSM, EPM and EDM, examination, diagnosis and limits of therapy. Indexed clinical text inspected; direct PMC page intermittently challenged access.
- Merck Veterinary Manual: Equine protozoal myeloencephalitis
Source update: 2024-07. Most recent check: 2026-11-02.
Protozoal causes, neurologic presentation, serum-versus-CSF interpretation, professional treatment and relapse; no drug doses or organism manipulation.
- ACVIM / Journal of Veterinary Internal Medicine: Equine protozoal myeloencephalitis: an updated consensus statement
Source update: 2016. Most recent check: 2026-11-02.
Parasite biology, exposure versus disease, diagnostic exclusion and evidence-based care principles; no drug-dose or CSF-collection instructions.
- Cornell University Animal Health Diagnostic Center: Equine protozoal myeloencephalitis testing
Source update: Not provided. Most recent check: 2026-11-02.
Diagnostic laboratory interpretation: positive serum antibody demonstrates exposure, not proof of clinical disease; testing must accompany neurologic assessment.
- American Association of Equine Practitioners: Infectious disease guidelines: equine protozoal myeloencephalitis
Source update: 2021. Most recent check: 2026-11-02.
Official guideline causes, transmission and clinical management principles; no drug doses, animal experimentation or diagnostic collection procedures.
